Nektar Therapeutics (NASDAQ:NKTR) Earns Market Perform Rating from William Blair
Nektar Therapeutics (NASDAQ:NKTR – Get Free Report)‘s stock had its “market perform” rating reissued by analysts at William Blair in a research note issued to investors on Thursday,RTT News reports. Several other research analysts also recently commented on the company. HC Wainwright reaffirmed a “buy” rating and issued a $6.50 price objective on shares of […]
Nektar Therapeutics (NASDAQ:NKTR – Get Free Report)‘s stock had its “market perform” rating reissued by analysts at William Blair in a research note issued to investors on Thursday,RTT News reports. Several other research analysts also recently commented on the company. HC Wainwright reaffirmed a “buy” rating and issued a $6.50 price objective on shares of […]
